

Official
FD
5-10-01



RESTRICTION ELECTION FACSIMILE TRANSMISSION

BEST AVAILABLE COPY

DATE: May 9, 2001

FROM/ATTORNEY: Norman Hansen

FIRM: Fulbright + Jaworski

PAGES, INCLUDING COVERSHEET: 3

PHONE NUMBER: (202) 318-3168

TO EXAMINER: A. Dechant

ART UNIT: 1644

SERIAL NUMBER: 09/626,617

FAX/TELECOPIER NUMBER: (703) 308-4315 (703) 305-7401


PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED ONLY
FOR RESPONSES TO RESTRICTIONS.

COMMENTS: _____

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE
TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 37 CFR 2.101, THE FILING DATE ASSIGNED EACH OFFICIAL FAX TRANSMISSION WILL BE
DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT
DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE
OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED
STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS
INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED
RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY
ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD
BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR,
PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.



BEST AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Laura Dumoutier, et al.
Application No. : 09/626,617
Filed : July 27, 2000
For : ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T
CELL INDUCIBLE FACTORS, OR INTERLEUKIN-21, THE
PROTEINS ENCODED, AND USES THEREOF
Art Unit : 1644
Examiner : A. Decloux

May 9, 2001

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

**RESPONSE TO
RESTRICTION REQUIREMENT**

In response to the restriction requirement of April 20, applicants respond as follows.

With respect to election of an allegedly separate group, Group I, claims 1-12 are elected.

In accordance with point 4 of the action, the following further elections are made:

- A. Specific STAT transcription factor: STAT-3 (claims 2 and 3)
- B. Specific IL-TIP/IL-21: mammalian/human (claims 4 and 5)
- C. Specific acute phase protein: serum amyloid A (claim 9)
- D. Specific cell: liver cell (claim 8)


1,UD 5664 US (10017134) - JFI/NDII

The claims reading on this election are claims 1-12.
Examination is requested.

BEST AVAILABLE COPY

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By: 
Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000

075029132v1<